Project Grant F31DA060678

Award Date 6/26/25
Completion Date 12/31/26
Dollars Obligated $84K
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Ann Arbor, MI 48109, USA
Similar Awards
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $421,200 to Oregon Health & Science University (OHSU) to develop new chemical biology tools to study the role of cannabinoid receptors in opioid use disorder. The key objectives are to expand OHSU's existing toolkit of fluorescent cannabinoid receptor probes and photoswitches to include the less-studied GPR55 receptor, and then apply these...
The National Institute of Neurological Disorders and Stroke (NINDS) awarded a $327,864 Project Grant under the Drug Abuse and Addiction Research Programs (CFDA 93.279) to Opsin Biotherapeutics Inc. to develop an optogenetic pain modulator for non-opioid chronic pain management. The project aims to optimize the optical delivery and wireless stimulation device for the Multi-Characteristic Opsin (MCO) that can be delivered to pain-sensing neurons and stimulated to minimize pain perception. The...
This federal Project Grant award of $1,213,117 was provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279). The objective is to develop novel chemical probes targeting the sodium binding site of the mu opioid receptor (MOR) to achieve functional selectivity and therapeutic benefits. The primary products/services include: Synthesis and pharmacological characterization of bitopic ligands that engage both the orthosteric and...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $772,800.00 to the University of Florida to conduct research aimed at identifying and pharmacologically targeting novel modulators of the mu-opioid receptor (MOR) signaling pathway. The overarching goal is to dissociate the beneficial analgesic effects of opioids from their harmful addictive properties by developing precision pharmacological...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), totaling $945,966 over the period of September 30, 2024 to July 31, 2029, will support research to unravel the neurobiological mechanisms by which the neuropeptide PEN and its receptor GPR83 interact with the mu-opioid receptor (MOR) in the periaqueductal gray (PAG) region of the brain. The goal is to determine if targeting the PEN-GPR83 pathway...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to establish OPRM1 exon 7-associated variants as novel therapeutic targets for mitigating adverse effects of clinically used mu opioids without altering analgesia in pain management. The $2,902,673 award, spanning September 2024 to May 2029, supports research at Rutgers, The State University of New Jersey, to characterize antisense oligonucleotides...
The University of Michigan was awarded a $2.7 million Trans-NIH Research Support Project Grant from the Department of Health and Human Services National Institutes of Health Office of the Director to develop new classes of optogenetic and chemogenetic tools with feedback control. The three-year award running from August 15, 2022 to August 14, 2025 will support the design of the first closed-loop chemogenetic tool with feedback control to suppress irregularly high neuronal activity, as well as...
This $1,370,628 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) aims to investigate the mechanisms and regulators of kappa opioid receptor (KOR) signaling. The research at The Washington University, to be conducted from June 15, 2024 to March 31, 2029, seeks to identify the molecular pharmacology of KOR, with the goal of exploring alternative treatments for pain and related conditions. The study will define the...
This $220,668 Project Grant, awarded by the National Institute on Drug Abuse under the Drug Use and Addiction Research Programs (CFDA 93.279), supports the development of a novel opioid adjuvant by Amalgent Therapeutics, Inc. The adjuvant aims to increase the pain-relieving efficacy of opioids, allowing for substantial reductions in opioid doses and mitigating the risks of opioid abuse, tolerance, and ineffectiveness for neuropathic pain. The project will investigate the mechanism of action...
This $858,600 Project Grant was awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) to the University of Pittsburgh. The grant aims to identify and validate G protein-coupled receptors (GPCRs) expressed by somatostatin-expressing inhibitory neurons in the prefrontal cortex that could be targeted for developing new treatments for opioid use disorder (OUD). The research will use an unbiased transcriptomics approach to identify...

OPTIMIZING CHEMICAL- AND LIGHT-DEPENDENT PROTEIN SWITCHES FOR CONTROLLING OPIOID PEPTIDE ACTIVITY WITH TEMPORAL CONTROL - PROPOSAL SUMMARY THE STUDY OF OPIOID RECEPTORS IS ESSENTIAL TO GAIN INSIGHT INTO THE MECHANISMS UNDERLYING THE EFFECTS OF OPIOID MEDICATIONS SUCH AS PAIN RELIEF AND ADDICTION. THE MU OPIOID RECEPTOR (MOR) IS PARTICULARLY IMPORTANT IN PAIN MODULATION, WITH ACTIVATION REDUCING PAIN SENSATION AS WELL AS INDUCING EUPHORIA AND RELAXATION. UNDERSTANDING THE MOLECULAR AND CELLULAR INTERACTIONS OF OPIOID RECEPTORS HAS THE POTENTIAL TO INFORM THE DEVELOPMENT OF SAFER PAIN MANAGEMENT STRATEGIES, NOVEL OPIOID MEDICATIONS, AND INTERVENTIONS TO ADDRESS THE HARMFUL ADDICTIVE PROPERTIES. PROTEIN TOOLS HAVE BEEN INSTRUMENTAL IN PROVIDING INSIGHTS INTO OPIOID RECEPTOR FUNCTION AND HAVE AIDED IN THE DEVELOPMENT OF SELECTIVE OPIOID RECEPTOR MODULATORS AS WELL AS FURTHERING NEUROSCIENCE RESEARCH. CHEMOGENETICS AND OPTOGENETICS ARE TWO POWERFUL TOOLS USED TO MANIPULATE AND STUDY SPECIFIC NEURAL CIRCUITS WITH HIGH TEMPORAL AND SPATIAL PRECISION. BOTH TECHNIQUES HAVE UNIQUE ADVANTAGES. CHEMOGENETIC INVOLVES THE USE OF SMALL MOLECULES TO CONTROL CELLULAR ACTIVITY GENETICALLY. ONE SIGNIFICANT ADVANTAGE OF CHEMOGENETICS IS ITS VERSATILITY. IT CAN BE USED IN A WIDE RANGE OF EXPERIMENTAL SYSTEMS, INCLUDING CELL CULTURES, SLICE PREPARATIONS, AND INTACT ANIMALS, ALLOWING TO STUDY NEURAL CIRCUITS IN A VARIETY OF CONTEXTS. OPTOGENETICS, ON THE OTHER HAND, INVOLVES THE USE OF GENETICALLY ENCODED PROTEINS THAT CAN BE ACTIVATED BY LIGHT. THIS ALLOWS FOR PRECISE, MILLISECOND-SCALE CONTROL OF NEURAL ACTIVITY, ENABLING THE PRECISE MANIPULATION OF NEURAL CIRCUITS WITH HIGH TEMPORAL RESOLUTION. OPTOGENETICS CAN ALSO BE USED TO TARGET SPECIFIC CELL TYPES, SUCH AS EXCITATORY OR INHIBITORY NEURONS, ALLOWING FOR THE SELECTIVE MANIPULATION OF SPECIFIC NEURAL CIRCUITS. THE CHEMOGENETIC AND OPTOGENETIC APPROACH CAN BE USED TO STUDY A WIDE RANGE OF BIOLOGICAL PROCESSES, INCLUDING INTRACELLULAR SIGNALING, TRANSCRIPTIONAL REGULATION, AND PROTEIN-PROTEIN INTERACTIONS. IN MY LABORATORY, WE HAVE DEVELOPED A CHEMOGENETIC TOOL CALLED CHEMICAL ACTIVATED PROTEIN DOMAIN (CAPS), WHICH OFFERS SEVERAL ADVANTAGES OVER OTHER CHEMOGENETIC APPROACHES. THE ADVANTAGES OF CAPS INCLUDE PRECISE, NON-TOXIC CONTROL OF PROTEIN ACTIVATION, OFFERING A POTENT TOOL FOR PEPTIDE THERAPY DEVELOPMENT AND BIOLOGICAL STUDIES. HERE, WE DEVELOPED A PLATFORM TO IMPROVE PEPTIDE CAGING OF CHEMOGENETIC AND OPTOGENETIC TOOLS, SPECIFICALLY CHEMICAL ACTIVATED PROTEIN (CAP) TO CONTROL OPIOID PEPTIDES. WE SUCCESSFULLY EVOLVED CAPC AND CAPN LIBRARIES AND DEMONSTRATED THAT IT CAGES THE PEPTIDE MORE EFFICIENTLY, RESULTING IN LESS LEAKY BINDING IN THE ABSENCE OF SHIELD-1. THESE TOOLS ARE INTENDED TO BE USED IN ANIMAL MODELS TO ADVANCE OUR UNDERSTANDING OF PEPTIDE-RELATED MECHANISMS IN VIVO AND TO POTENTIALLY DEVELOP NEW INTERVENTIONS FOR VETERINARY USE.

Posted 12/26/24, 12:00 AM